Selected article for: "HIV human immunodeficiency virus and human immunodeficiency virus"

Author: Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Title: Network-based Drug Repurposing for Human Coronavirus
  • Document date: 2020_2_5
  • ID: b4mdiont_29
    Snippet: Toremifene (Z = -3.23, Figure 5A ), the first generation of nonsteroidal SERM, exhibits potential effects in blocking various viral infections, including MERS-CoV, SARS-CoV, and Ebola virus in established cell lines [16, 35] . Interestingly, different from the classical ESR1-related antiviral pathway, toremifene prevents fusion between the viral and endosomal membrane by interacting with and destabilizing the virus membrane glycoprotein, and even.....
    Document: Toremifene (Z = -3.23, Figure 5A ), the first generation of nonsteroidal SERM, exhibits potential effects in blocking various viral infections, including MERS-CoV, SARS-CoV, and Ebola virus in established cell lines [16, 35] . Interestingly, different from the classical ESR1-related antiviral pathway, toremifene prevents fusion between the viral and endosomal membrane by interacting with and destabilizing the virus membrane glycoprotein, and eventually inhibiting viral replication [36] . As shown in Figure 5B , toremifene potentially affects several key host proteins associated with HCoV, such as RPL19, HNRNPA1, NPM1, EIF3I, EIF3F, and EIF3E [37, 38] . Equilin (Z = -2.52 and GSEA score = 3), an estrogenic steroid produced by horses, also has been proven to have moderate activity in inhibiting the entry of Zaire Ebola virus-glycoprotein and human immunodeficiency virus (ZEBOV-GP/HIV) [17] . Altogether, network-predicted SERMs (such as toremifene and equilin) offer potential repurposable candidates for HCoVs.

    Search related documents:
    Co phrase search for related documents
    • antiviral pathway and classical antiviral pathway: 1
    • antiviral pathway and Ebola virus: 1, 2
    • antiviral pathway and host protein: 1, 2, 3, 4, 5, 6, 7
    • antiviral pathway and human immunodeficiency: 1, 2
    • antiviral pathway and human immunodeficiency virus: 1, 2
    • cell line and Ebola virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • cell line and establish cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • cell line and host protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell line and human immunodeficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • cell line and human immunodeficiency virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • cell line and human immunodeficiency virus virus glycoprotein: 1
    • cell line and moderate activity: 1, 2, 3, 4, 5
    • Ebola virus and endosomal viral membrane: 1, 2, 3, 4
    • Ebola virus and endosomal viral membrane fusion: 1, 2, 3, 4
    • Ebola virus and host protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • Ebola virus and human immunodeficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • Ebola virus and human immunodeficiency virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • Ebola virus and moderate activity: 1
    • endosomal viral membrane and human immunodeficiency virus: 1